In antipsychotic drug development, Ace Therapeutics' microdialysis multi-probe technology can help researchers understand drug distribution, metabolism, and clearance in the brain to better optimize drug design and use.

Introduction of Multiple Probes and Combined in Antipsychotic Drug Development

The microdialysis technique is capable of sampling and collecting small molecular weight substances from the interstitial space. It is a widely used method in neuroscience and is one of the few available techniques to quantify neurotransmitters, peptides, and hormones in behaving animals. The microdialysis multi-probe technique allows the monitoring of neurotransmitters and other molecules in interstitial tissue fluids. This method is widely used to sample and quantify brain and peripheral neurotransmitters, neuropeptides, and hormones. Depending on the availability of appropriate analytical assays, virtually all soluble molecules in interstitial space fluids can be measured by microdialysis.

Fig. 1 Neural probe system including technical details regarding the perfusion and the interface unit. (Petit-Pierre G, et al., 2017)

Multiple Probes and Combined Services

Ace Therapeutics' extensive experience in microdialysis offers a wide range of options to combine various probes in a wide range of applications. We can customize assays by combining PK or PD microdialysis techniques or by combining microdialysis with other methods, such as behavioral or EEG measurements. Key applications of multi-probe approaches include real-time measurement of pharmacodynamic changes in neurotransmitters, modulators, and proteins while collecting free drug concentrations to establish an accurate PK/PD relationship.

Our Microdialysis Multi-probe Technology in Antipsychotics Discovery

• Drug metabolism studies: We monitor the concentration changes of drug metabolites in the brain by microdialysis multi-probe technology, which can help you understand the metabolic pathway and metabolic rate of drugs in the brain.
• Drug absorption studies: We monitor the concentration changes of drugs in the brain by microdialysis multi-probe technology, which can help you understand the permeability of drugs in the blood-brain barrier, absorption rate, and other information.
• Drug target studies: We monitor the concentration changes of drugs in specific regions of the brain by microdialysis multi-probe technology, which can help you understand the selectivity, affinity, and other information of drugs to the target.

Advantages of Our Technology in The Development of Antipsychotics

• Real-time: we can monitor changes in the concentration of neurotransmitters, drugs, and metabolites in the brain in real-time by using the microdialysis multiprobe, thus we can quickly obtain information about the dynamics of drugs in the brain.
• High sensitivity: We can monitor very small molecular concentration changes with the microdialysis multiprobe, thus detecting very low doses of drugs.
• High selectivity: We can monitor several different molecules simultaneously with the microdialysis multiprobe, so that we can distinguish the interaction between different molecules.
• High spatial resolution: We can selectively monitor changes in molecular concentrations in a specific brain region with microdialysis multiprobes, thus providing very high spatial resolution.
• Cost-effective: we can sample the same brain multiple times, thus reducing the number of experimental animals and the number of drugs used. As a result, the microdialysis multiprobe is relatively inexpensive compared to other techniques.

Ace Therapeutics' microdialysis multi-probe technology has very high real-time, sensitivity, and spatial resolution, allowing rapid access to information about the dynamics of drugs in the brain. We are committed to providing you with timely assistance in the field of antipsychotic drug development. If you are interested in this service, please make an inquiry to learn how we can support you in your project.

Reference

1. Petit-Pierre G, et al. In vivo neurochemical measurements in cerebral tissues using a droplet-based monitoring system. Nat Commun. 2017, 8(1):1239.